Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

IlluminOss Medical announces conditional FDA approval for clinical trials of Photodynamic Bone Stabilization System in US

IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, announced that it has received conditional approval from the FDA to conduct a clinical trial for the treatments of impending and pathologic fractures in the humerus due to metastatic carcinoma.

IlluminOss expects to begin enrolling clinical sites and initiate the trial shortly.

IlluminOss’ Photodynamic Bone Stabilization System (PBSS) is the world’s first and only system of its kind and offers significant advantages for the treatment of complex fractures. It is commercially available in international markets and has been in clinical use since 2010.

IlluminOss’ novel approach has proven successful in its widespread use in Europe, where PBSS has been used in the treatment of over 700 patients. Benefits observed from the use of the product in patients include smaller incisions, shorter procedure times, and more rapid post-procedure patient mobility with reduced hospital stays and lower complication rates.

The minimally invasive procedure incorporates the use of a thin walled PET balloon that is infused with a liquid monomer and inserted into the intramedullary canal of the bone conforming to the shape of the patient’s specific bone.

The device forms as an implant once the surgeon activates the visible light delivered within the PET balloon. Once cured, the implant provides longitudinal strength and rotational stability over the length of the implant.

Dr. Martin Malawer, director, Orthopedic Surgical Oncology and Professor of Orthopedic Surgery at George Washington University Hospital and Professor (Clinical Scholar) of Orthopedic Surgery at Georgetown University, is positioned to lead the first U.S. trial of PBSS. Dr. Malawer is widely respected for pioneering many surgical techniques used today in cancer centers throughout the world. In the trial, he will be applying IlluminOss’ technology to the treatment of metastatic lesions.

"From what I have seen to date, IlluminOss’ Photodynamic Bone Stabilization System could prove to be a true disruptive technology in the treatment of pathological and non-pathological fractures by orthopedic surgeons," said Dr. Malawer. "This technology will potentially reduce surgery time and morbidity rates, as well as lessen complications and improve patient outcomes."